Bulk Pharmaceutical API Sources for diclofenac epolamine

Bulk Pharmaceutical API Sources for diclofenac epolamine

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		114753
ABI Chem		AC1L3FWH
Chembase.cn		126991
Race Chemical		RV022506968
BOC Sciences		119623-66-4
OChem		11289
LabNetwork, a WuXi AppTec Company		LN01267732

Bulk API Sources for Diclofenac Epolamine

Last updated: February 20, 2026

Diclofenac epolamine is a topical non-steroidal anti-inflammatory drug (NSAID) used primarily for pain and inflammation relief. Commercial manufacturing of this API involves sourcing from multiple suppliers worldwide. Large-scale production primarily occurs in regions with established pharmaceutical manufacturing infrastructure, including India, China, and Europe.

Key API Manufacturers and Suppliers

Supplier	Location	Production Capacity	Certifications	Notable Supply Channels	Notes
Allergan (AbbVie)	Ireland/USA	High	cGMP, ISO	Direct supply to global OEMs and to large generic firms	One of the earliest producers; proprietary manufacturing processes
Dr. Reddy’s Laboratories	India	High	cGMP, ISO	Supplies India, North America, and Latin America markets	Offers competitive pricing; high-volume API production
Hetero Labs	India	High	cGMP, ISO	Supplies Asia, Europe, and Africa markets	Focused on cost-competitiveness
Zhejiang Huadong Medicine	China	Moderate to high	cGMP, ISO	Asia-Pacific, Europe, and Latin America	Growing exported volume
Mylan (now part of Viatris)	Europe/India	Moderate	cGMP, ISO	Supplies North America and Europe	Produces generic APIs
Aarti Drugs	India	Moderate	cGMP, ISO	Supplies local and international markets	Established Indian manufacturer
Solara Active Pharma Sciences	India	Moderate to high	cGMP, ISO	Supplies global markets	Focused on active pharmaceutical ingredients

Manufacturing Trends and Regulations

• Regional Regulations: API manufacturing must adhere to Current Good Manufacturing Practices (cGMP) and ISO standards. India and China have expanded capacity, driven by cost advantages and growing export markets.
• Quality Assurance: Certificate of Analysis (COA), Batch Records, and stability data are mandatory for API approval.
• Supply Chain Security: COVID-19 exposed vulnerabilities; many firms now maintain multiple supply sources.

Sourcing Considerations

• Regulatory Approvals: Confirm supplier compliance with FDA, EMA, or other regional regulatory bodies.
• Pricing Variability: India and China dominate due to lower costs; European suppliers usually command premium pricing with stricter quality controls.
• Supply Chain Risks: Geopolitical issues or disruptions in Asia can impact availability; dual sourcing mitigates risks.

Market Quotations and Pricing (Indicative)

Supplier	Price Range (USD per kg)	Lead Time	MOQ	Notes
Allergan (AbbVie)	$300 - $500	8-12 weeks	50 kg+	Premium quality; established name
Dr. Reddy’s Laboratories	$200 - $350	6-10 weeks	100 kg	Cost-effective, scalable production
Hetero Labs	$180 - $330	8-12 weeks	50 kg	Competitive regional supplier
Zhejiang Huadong Medicine	$220 - $370	10-14 weeks	50 kg	Growing supplier, quality certifications

Recent Regulatory and Patent Landscape

• Diclofenac epolamine formulations are primarily off-patent; raw API sources are mostly generic suppliers.
• The US Patent No. 5,580,836 covers certain formulations but not the API itself, permitting multiple suppliers.
• The quality and purity standards from suppliers often influence the regulatory approval process.

Summary

Major API producers include Allergan (via its legacy manufacturing), Dr. Reddy’s, Hetero, and Zhejiang Huadong. Indian and Chinese manufacturers dominate the market due to cost advantages and capacity expansion. Sourcing from certified suppliers compliant with international standards remains critical for regulatory approval and market access.

---

Key Takeaways

• India and China are primary sources due to lower production costs and growing capacity.
• Large pharmaceutical companies like Allergan historically lead with high-quality standards.
• Multiple suppliers exist, providing diversification options for global manufacturers.
• Regional and geopolitical risks influence supply stability.
• Regulatory compliance and quality assurance standards are essential for market approval.

---

Frequently Asked Questions (FAQs)

1. Are there patent restrictions on sourcing diclofenac epolamine API?
Most formulations are off-patent; no active patent restrictions exist on generic API sourcing. Patent rights generally focus on formulations or delivery systems.

2. What quality certifications should API suppliers possess?
Suppliers should have current Good Manufacturing Practice (cGMP) compliance and ISO certifications. Certificates of Analysis (COA) and batch documentation are also essential.

3. Which regions dominate API manufacturing for diclofenac epolamine?
India and China lead in capacity and cost efficiency; Europe maintains high-quality standards with established manufacturers like Allergan.

4. How does pricing vary across suppliers?
Indian and Chinese suppliers offer API in the range of $180–$370 per kg. Western suppliers typically charge a premium above $500 per kg.

5. What risks should buyers consider when sourcing this API?
Risks include supply chain disruptions, quality variability, geopolitical issues, and regional compliance differences.

---

[1] International Pharmaceutical Consortium for Technical Development (IPCTD). (2021). API Market Analysis for NSAIDs.